Prohost Letters
Premium
Prohost Letter #378 Part 2
Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The ASCO meeting projected the huge advancement in the understanding, diagnosing and treating cancer. What looked...
P
Prohost Biotech
1 min read
7
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
Advaxis (ADXS)
Agenus (AGEN)
American Society of Clinical Oncology (ASCO)
Amgen (AMGN)
Ariad Pharmaceuticals (ARIA)
Bellicum Pharmaceuticals Inc (BLCM)
Bristol-Myers Squibb (BMY)
CAR-T
Celldex Therapeutics (CLDX)
Chimerix Inc (CMRX)
Compugen (CGEN)
Endocyte (ECYT)
Exelixis (EXEL)
Five Prime Therapeutics (FPRX)
Gilead Sciences (GILD)
Halozyme Therapeutics (HALO)
Illumina (ILMN)
ImmunoGen (IMGN)
Incyte (INCY)
Jazz Pharmaceuticals (JAZZ)
Juno Therapeutics (JUNO)
Kite Pharma - A Gilead Company
Merck (MRK)
Momenta Pharmaceuticals (MNTA)
Nektar Therapeutics (NKTR)
Pfizer (PFE)
Prohost Portfolio
Regeneron Pharmaceuticals (REGN)
Sanofi (SNY)
Seagen Inc (SGEN)
Sequenom (SQNM)
Theravance Inc (THRX)
Xoma (XOMA)
Comments (0)
Please sign in to join the discussion